A total of 151 M&A deals (pending and completed) were announced in the Global Pharmaceuticals sector, in the last twelve months resulting in a total deal value of over $124,520.3 million. In the LTM period, December 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $24,884.6 million, resulting in an average deal value of $1,914.2 million during that month. On the other hand, the month of November 2021 was the most prolific in terms of deal volume, recording a total of 22 deals, resulting in an average deal value of $344.3 million during that month.
Of the 151 deals, the deal secured between CSL Ltd and Vifor Pharma Ltd, was the largest M&A deal in the Global Pharmaceuticals sector, which was valued at $12,300.0 million and was completed on December 14, 2021. The second-largest deal was between Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd, while the third-largest deal was between Merck & Co Inc and Acceleron Pharma Inc. The Pfizer Inc-Biohaven Pharmaceutical Holding Company Ltd deal and the Merck & Co Inc-Acceleron Pharma Inc deal were valued at $12,210.5 million and $11,500.0 million, respectively. The fourth-largest deal was between Danaher Corp-Aldevron LLC valued at $9,600.0 million, whereas the deal between Pfizer Inc-Arena Pharmaceuticals Inc valued at $6,700.0 million was the fifth-largest deal.
Cumulatively, the top five deals amounted to $52,310.5 million and accounted for nearly 42.01% of the total deals (by value) announced during the last twelve months. By region, North America accounted for 71.56% of the total M&A deals done globally, and recorded a total deal value of $89,275.6 million, which accounted for 49.67% of the total deal size on a global scale.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward